001     258919
005     20231120155349.0
024 7 _ |a 10.1016/S1474-4422(23)00131-X
|2 doi
024 7 _ |a pmid:37236211
|2 pmid
024 7 _ |a 1474-4422
|2 ISSN
024 7 _ |a 1474-4465
|2 ISSN
024 7 _ |a altmetric:148884872
|2 altmetric
037 _ _ |a DZNE-2023-00691
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Duering, Marco
|b 0
245 _ _ |a Neuroimaging standards for research into small vessel disease-advances since 2013.
260 _ _ |a London
|c 2023
|b Lancet Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1692960377_28578
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cerebral small vessel disease (SVD) is common during ageing and can present as stroke, cognitive decline, neurobehavioural symptoms, or functional impairment. SVD frequently coexists with neurodegenerative disease, and can exacerbate cognitive and other symptoms and affect activities of daily living. Standards for Reporting Vascular Changes on Neuroimaging 1 (STRIVE-1) categorised and standardised the diverse features of SVD that are visible on structural MRI. Since then, new information on these established SVD markers and novel MRI sequences and imaging features have emerged. As the effect of combined SVD imaging features becomes clearer, a key role for quantitative imaging biomarkers to determine sub-visible tissue damage, subtle abnormalities visible at high-field strength MRI, and lesion-symptom patterns, is also apparent. Together with rapidly emerging machine learning methods, these metrics can more comprehensively capture the effect of SVD on the brain than the structural MRI features alone and serve as intermediary outcomes in clinical trials and future routine practice. Using a similar approach to that adopted in STRIVE-1, we updated the guidance on neuroimaging of vascular changes in studies of ageing and neurodegeneration to create STRIVE-2.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases
|2 MeSH
650 _ 2 |a Activities of Daily Living
|2 MeSH
650 _ 2 |a Neuroimaging
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging: methods
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Cognitive Dysfunction
|2 MeSH
650 _ 2 |a Cerebral Small Vessel Diseases: diagnostic imaging
|2 MeSH
700 1 _ |a Biessels, Geert Jan
|b 1
700 1 _ |a Brodtmann, Amy
|b 2
700 1 _ |a Chen, Christopher
|b 3
700 1 _ |a Cordonnier, Charlotte
|b 4
700 1 _ |a de Leeuw, Frank-Erik
|b 5
700 1 _ |a Debette, Stéphanie
|b 6
700 1 _ |a Frayne, Richard
|b 7
700 1 _ |a Jouvent, Eric
|b 8
700 1 _ |a Rost, Natalia S
|b 9
700 1 _ |a Ter Telgte, Annemieke
|b 10
700 1 _ |a Al-Shahi Salman, Rustam
|b 11
700 1 _ |a Backes, Walter H
|b 12
700 1 _ |a Bae, Hee-Joon
|b 13
700 1 _ |a Brown, Rosalind
|b 14
700 1 _ |a Chabriat, Hugues
|b 15
700 1 _ |a De Luca, Alberto
|b 16
700 1 _ |a deCarli, Charles
|b 17
700 1 _ |a Dewenter, Anna
|b 18
700 1 _ |a Doubal, Fergus N
|b 19
700 1 _ |a Ewers, Michael
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Field, Thalia S
|b 21
700 1 _ |a Ganesh, Aravind
|b 22
700 1 _ |a Greenberg, Steven
|b 23
700 1 _ |a Helmer, Karl G
|b 24
700 1 _ |a Hilal, Saima
|b 25
700 1 _ |a Jochems, Angela C C
|b 26
700 1 _ |a Jokinen, Hanna
|b 27
700 1 _ |a Kuijf, Hugo
|b 28
700 1 _ |a Lam, Bonnie Y K
|b 29
700 1 _ |a Lebenberg, Jessica
|b 30
700 1 _ |a MacIntosh, Bradley J
|b 31
700 1 _ |a Maillard, Pauline
|b 32
700 1 _ |a Mok, Vincent C T
|b 33
700 1 _ |a Pantoni, Leonardo
|b 34
700 1 _ |a Rudilosso, Salvatore
|b 35
700 1 _ |a Satizabal, Claudia L
|b 36
700 1 _ |a Schirmer, Markus D
|b 37
700 1 _ |a Schmidt, Reinhold
|b 38
700 1 _ |a Smith, Colin
|b 39
700 1 _ |a Staals, Julie
|b 40
700 1 _ |a Thrippleton, Michael J
|b 41
700 1 _ |a van Veluw, Susanne J
|b 42
700 1 _ |a Vemuri, Prashanthi
|b 43
700 1 _ |a Wang, Yilong
|b 44
700 1 _ |a Werring, David
|b 45
700 1 _ |a Zedde, Marialuisa
|b 46
700 1 _ |a Akinyemi, Rufus O
|b 47
700 1 _ |a Del Brutto, Oscar H
|b 48
700 1 _ |a Markus, Hugh S
|b 49
700 1 _ |a Zhu, Yi-Cheng
|0 P:(DE-HGF)0
|b 50
700 1 _ |a Smith, Eric E
|b 51
700 1 _ |a Dichgans, Martin
|0 P:(DE-2719)2000030
|b 52
|u dzne
700 1 _ |a Wardlaw, Joanna M
|b 53
773 _ _ |a 10.1016/S1474-4422(23)00131-X
|g Vol. 22, no. 7, p. 602 - 618
|0 PERI:(DE-600)2079704-7
|n 7
|p 602 - 618
|t The lancet / Neurology
|v 22
|y 2023
|x 1474-4422
856 4 _ |u https://www.sciencedirect.com/science/article/pii/S147444222300131X
856 4 _ |u https://pub.dzne.de/record/258919/files/DZNE-2023-00691_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/258919/files/DZNE-2023-00691_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:258919
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 52
|6 P:(DE-2719)2000030
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2023
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-24
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LANCET NEUROL : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-24
915 _ _ |a IF >= 40
|0 StatID:(DE-HGF)9940
|2 StatID
|b LANCET NEUROL : 2022
|d 2023-10-24
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21